LEXARIA BIOSCIENCE CORP. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
LEXARIA BIOSCIENCE CORP. (LEXX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 45.00 thousand shares for the 9-month period ending 2026-05-31, per its 10-Q filed 2026-07-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-07-13
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-08-31 was 260.00K shares, a 1200.00% increase year-over-year.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-05-31 was 351.50K shares.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-02-29 was 0.00 shares, a 100.00% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-11-30 was 85.00K shares, a 90.58% increase year-over-year.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 696.50K shares, a 900.72% increase from fiscal 2023.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 69.60K shares, a 68.65% decline from fiscal 2022.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 222.00K shares, a 37.38% increase from fiscal 2021.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 161.60K shares, a 0.00% change from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-05-31 | 45.00K shares 10-Q · filed 2026-07-13 | |||||
| 2025-08-31 | 586.50K shares 10-Q · filed 2026-07-13 | |||||
| 2024-08-31 | 260.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-28 | 611.50K shares derived: sum of 2 quarters · filed 2025-11-28 | 611.50K shares derived: sum of 3 quarters · filed 2025-11-28 | 696.50K shares 10-K · filed 2025-11-28 | ||
| 2024-05-31 | 351.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-07-12 | 351.50K shares derived: sum of 2 quarters · filed 2024-07-12 | 436.50K shares 10-Q · filed 2024-07-12 | 456.50K shares derived: sum of 4 quarters · filed 2024-11-26 | ||
| 2024-03-15 | 200.00K shares 10-K · filed 2024-11-26 | |||||
| 2024-02-29 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-04-09 | 85.00K shares 10-Q · filed 2024-04-09 | 105.00K shares derived: sum of 3 quarters · filed 2024-11-26 | 105.00K shares derived: sum of 4 quarters · filed 2024-11-26 | ||
| 2023-11-30 | 85.00K shares 10-Q · filed 2024-01-12 | 105.00K shares derived: sum of 2 quarters · filed 2024-11-26 | 105.00K shares derived: sum of 3 quarters · filed 2024-11-26 | 110.00K shares derived: sum of 4 quarters · filed 2024-11-26 | ||
| 2023-08-31 | 20.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | 20.00K shares derived: sum of 2 quarters · filed 2024-11-26 | 25.00K shares derived: sum of 3 quarters · filed 2024-11-26 | 69.60K shares 10-K · filed 2024-11-26 | ||
| 2023-05-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-07-14 | 5.00K shares derived: sum of 2 quarters · filed 2023-07-14 | 49.60K shares 10-Q · filed 2023-07-14 | 189.80K shares derived: sum of 4 quarters · filed 2023-11-20 | ||
| 2023-02-28 | 5.00K shares derived: 10-Q 6 month − 10-Q/A 3 month · filed 2023-04-14 | 49.60K shares 10-Q · filed 2023-04-14 | 189.80K shares derived: sum of 3 quarters · filed 2023-11-20 | 226.50K shares derived: sum of 4 quarters · filed 2023-11-20 | ||
| 2022-11-30 | 44.60K shares 10-Q/A · filed 2023-01-18 | 184.80K shares derived: sum of 2 quarters · filed 2023-11-20 | 221.50K shares derived: sum of 3 quarters · filed 2023-11-20 | 221.50K shares derived: sum of 4 quarters · filed 2023-11-20 | ||
| 2022-08-31 | 140.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-20 | 176.90K shares derived: sum of 2 quarters · filed 2023-11-20 | 176.90K shares derived: sum of 3 quarters · filed 2023-11-20 | 222.00K shares 10-K · filed 2023-11-20 | ||
| 2022-05-31 | 36.70K shares 10-Q · filed 2022-07-14 | 36.70K shares derived: sum of 2 quarters · filed 2022-07-14 | 81.80K shares 10-Q · filed 2022-07-14 | 195.20K shares derived: sum of 4 quarters · filed 2022-11-28 | ||
| 2022-02-28 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-04-11 | 81.80K shares 10-Q · filed 2022-04-11 | 158.50K shares derived: sum of 3 quarters · filed 2022-11-28 | 240.00K shares derived: sum of 4 quarters · filed 2022-11-28 | ||
| 2021-11-30 | 81.80K shares 10-Q · filed 2022-01-14 | 158.50K shares derived: sum of 2 quarters · filed 2022-11-28 | 240.00K shares derived: sum of 3 quarters · filed 2022-11-28 | |||
| 2021-08-31 | 76.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-28 | 158.20K shares derived: sum of 2 quarters · filed 2022-11-28 | 161.60K shares 10-K · filed 2022-11-28 | 84.90K shares 10-K · filed 2021-11-29 | ||
| 2021-05-31 | 81.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-07-15 | 84.90K shares 10-Q · filed 2021-07-15 | ||||
| 2021-02-28 | 3.40K shares 10-Q · filed 2021-04-14 | |||||
| 2020-08-31 | -4.69M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-29 | -1.45M shares derived: sum of 2 quarters · filed 2021-11-29 | 0.00 shares derived: sum of 3 quarters · filed 2021-11-29 | 161.60K shares 10-K · filed 2021-11-29 | 4.85M shares 10-K · filed 2020-10-15 | |
| 2020-05-31 | 3.24M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-06-29 | 4.69M shares derived: sum of 2 quarters · filed 2020-06-29 | 4.85M shares 10-Q · filed 2020-06-29 | |||
| 2020-02-29 | 1.45M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-04-03 | 1.61M shares 10-Q · filed 2020-04-03 | ||||
| 2019-11-30 | 161.60K shares 10-Q · filed 2021-01-14 | |||||
| 2019-08-31 | 2.05M shares 10-K · filed 2020-10-15 | |||||
| 2018-08-31 | 2.02M shares 10-K · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |